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Backgrounds: Copeptin has been studied as an excellent predictor of outcome in a variety of
diseases, its value is even superior to that of B-type natriuretic peptide (BNP) in heart failure,
but little is known about its characteristics in acute respiratory distress syndrome (ARDS)/
acute lung injury (ALI). We sought to assess the diagnostic and prognostic value of copeptin
together with N-terminal pro-BNP (NT-proBNP) in patients with ARDS/ALI or cardiogenic pulmo-
nary edema (CPE).
Methods: Measurement of copeptin and NT-proBNP levels in plasma from 121 consecutive
patients with either ARDS/ALI or CPE enrolled in a prospective single center study.
Results: In a derivation cohort of 87 patients with ARDS/ALI and 34 patients with CPE, a copep-
tin threshold of >40.11 pmol/L provided a specificity of 88.2% and a sensitivity of 60.9% for the
diagnosis of ARDS/ALI, a NT-proBNP cut point of <2813 pg/ml had a specificity of 79.4% and
sensitivity of 65.5% for it. Multivariate Cox regression analysis showed that copeptin was the
strongest predictor for mortality in patients with ARDS/ALI [hazard ratio (HR) Z 4.72,
P < 0.001] and CPE (HR Z 3.52, P Z 0.019), the association between increasing copeptin
and death was statistically significant in patients with ARDS/ALI (HR Z 2.64, P Z 0.035) and
patients with CPE (HR Z 1.62, P Z 0.029).
Conclusion: Copeptin of >40.11 pmol/L had a high specificity for the diagnosis of ARDS/ALI in
patients presenting with ARDS/ALI or CPE. Compared to NT-proBNP, copeptin was a stronger
prognostic marker for short-term mortality.
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The pathophysiology of ARDS is complex and involve disor-
ders of the cardiopulmonary system. The differential
diagnosis is challenging in cases requiring distinction
between ARDS and CPE.1e3 The diagnosis of ARDS requires
the exclusion of left atrial hypertension, this is usually done
on the basis of clinical judgment along with echocardiog-
raphy and invasive hemodynamic monitoring. BNP and NT-
proBNP have been proved useful in excluding CPE and
identifying patients with ARDS,3e5 but the high rate of renal
dysfunction and aging in critically ill patients limit the
discriminative role of them.5
Arginine vasopressin (AVP) is a hormone with a lot of
functions, including endocrine, hemodynamic, and osmo-
regulatory effects.6 Observations have shown that AVP
levels increase in different states of shock and heart
failure.7,8 However, AVP is unstable in isolated plasma even
when stored 20 C and more than 90% of AVP in the
circulation is bound to platelets, thus these limitations
preclude its routine use. Copeptin, the C-terminal part of
the AVP precursor, is secreted together with AVP from the
neurohypophysis and much more stable.9 AVP and copeptin
showed a very good correlation in plasma samples of
healthy individuals and patients, thus copeptin is used as
a surrogate marker for mature AVP.10 Studies have indi-
cated copeptin is an excellent predictor of outcome in
heart failure and acute myocardial infarction, its value was
even superior to that of BNP.11,12 The prognostic role of
copeptin in lower respiratory tract infections and chronic
obstructive pulmonary disease (COPD) has been investi-
gated,13,14 and recent study has showed copeptin is a new
promising prognostic marker for short-term mortality
independently and additive to natriuretic peptide levels in
patients with acute dyspnea.15
Copeptin levels may mirror both the inflammatory
cytokine response and the presence of hemodynamic and
osmoregulatory disturbances, however, little is known
about its characteristics in ARDS. Herein, we planed
a prospective study to investigate the diagnostic and
prognostic value of copeptin together with NT-proBNP in
patients with ARDS/ALI or CPE. Furthermore, we studied
the additive prognostic value of changes in copeptin and
NT-proBNP levels over time.Materials and methods
Study population
The prospective, observational trial was undertaken from
January 2010 to June 2011. A total of 121 consecutive
patients with ARDS/ALI or CPE admitted into the intensive
care unit (ICU) were included. Exclusion criteria included
age <18 years, lung cancer, immunosuppression due to
medication or disease and patients on hemodialysis.
Patients who had a mixed cause of pulmonary edema, with
risk factors and criteria for ARDS/ALI except for a transient
elevation in pulmonary artery occlusion pressure (PAOP) to
18 mmHg or higher, were excluded. The study protocol was
approved by the local ethics committee in accordance withthe Declaration of Helsinki. Written informed consent was
obtained from all participating patients.
Patients were enrolled within 12 h from the time of
admission to the ICU. Two expert intensivists blinded to
results of copeptin and NT-proBNP, reviewed all other
available clinical data and assigned the final diagnosis of
ARDS/ALI or CPE. In case of disagreement, they reviewed
the disputed cases together and reached a consensus.
Patients with ARDS/ALI met the following consensus defi-
nition: presence of a risk factor, acute onset of bilateral
infiltrates on chest radiography, severe hypoxemia with
a ratio of arterial oxygen partial pressure and inspiratory
oxygen fraction (PO2/FiO2) less than 300 for ALI and less
than 200 for ARDS, and no clinical evidence of elevated left
atrial pressure including PAOP <18 mmHg.2 CPE was defined
as pulmonary edema due to increased capillary hydrostatic
pressure secondary to elevated pulmonary venous pressure.
Patients with CPE was diagnosed by a combination of clin-
ical signs (gallop, jugular venous distension, systolic
hypertension); radiographic (cardiothoracic ratio of >0.53
and vascular pedicle width of >65 mm), electrocardio-
graphic (new ST-segment and T-wave changes), laboratory
(elevated troponinT of >0.1 ng/ml), and hemodynamic
findings (PAOP of 18 mmHg, decreased ejection fraction
of <45%, presence of severe left-sided valvular heart
disease [aortic or mitral stenosis or regurgitation]); and the
response to appropriate therapy (preload/afterload
reduction, treatment of ischemia or inotropic agents).16Data collection
Patients underwent an initial clinical assessment, invasive
hemodynamic monitoring, echocardiogram, pulmonary
function, CT angiography were performed according to the
treating physician, diagnostic uncertainty requiring inser-
tion of a Swan-Ganz catheter. Thus, invasive hemodynamic
monitoring was not performed in a majority of patients.
Based on the availability of all clinical information inte-
grated with echocardiogram, progression of the disease,
and response to therapy, intensivists made the final diag-
nosis. Acute Physiology and Chronic Health Evaluation
(APACHE)Ⅱscore17 and Lung Injury Score (LIS)18 were
calculated at enrollment. The primary clinical risk factor
for ARDS/ALI was classified as direct pulmonary (pneu-
monia, aspiration) or indirect non-pulmonary (non-pulmo-
nary sepsis, hemorrhagic shock, resuscitation, multiple
transfusion). For some analysis, the causes of ARDS/ALI
were also classified as sepsis related (sepsis as the cause of
ARDS/ALI) or non-sepsis related (all other causes of ARDS/
ALI, including hemorrhagic shock, aspiration, resuscitation,
multiple transfusion). Patients were followed for the
primary end point of 30-day mortality and the secondary
end points of the number of ventilator-free days (VFD) and
non-pulmonary organ failureefree days (OFD) over a 30-day
period after enrollment.
Blood samples for determination of copeptin, NT-proBNP
were collected at enrollment and 4 days later, samples
were frozen at 80 C after centrifugation. Copeptin
plasma concentration was determined using a novel
commercial sandwich immunoluminometric assay
(B.R.A.H.M.S LUMItest CT-proAVP, B.R.A.H.M.S AG,
1270 Q. Lin et al.Hennigsdorf/Berlin, Germany) as described in detail else-
where.9 The lower detection limit was 0.4 pmol/L and the
functional assay sensitivity (<20% interassay CV) was
<1 pmol/L. Median copeptin levels in 200 healthy individ-
uals was 3.7 pmol/L and the 97.5th percentile was
16.4 pmol/L. The NT-proBNP level was determined using
the Elecsys Electro-chemo luminescent assay (Cobas e411
analyzer; Roche Diagnostics; Mannheim, Germany), and this
assay has a detection limit of 5 pg/ml with measuring range
up to 35,000 pg/ml.
Statistics analysis
Continuous variables are presented as mean  standard
deviation (SD) or median (with interquartile range), and
categorical variables as numbers and percentages. Plasma
levels of copeptin, NT-proBNP were log-transformed to
achieve a normal distribution. Two-group was compared
with unpaired Student’s t-test or ManneWhitney test for
continuous variables and chi-square for categorical vari-
ables. For multigroup comparison, One-way AVONA was
used with least-significance- difference (LSD) evaluation.
Correlations among continuous variables were assessed by
the Pearson correlation analysis for variables followed
normal distribution and Spearman rank analysis for those
that did not. Receiver operating characteristic (ROC) curves
were utilized to evaluate the accuracy of copeptin, NT-
proBNP to diagnose ARDS/ALI and CPE. ROC were calcu-
lated using STATA (version 9.0, Statacorp, Texas, USA). Cox
regression analysis was assessed by univariate and multi-
variate analysis to identify independent predictors of
outcome. All probabilities were two tailed and P < 0.05 was
regarded as significant. Data were statistically analyzed
with SPSS 16.0 software (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
A total of 121 patients, 87 patients with ARDS/ALI and 34
patients with CPE were enrolled in the study. Causes of
ARDS/ALI included pneumonia in 31 patients (35.6%), non-
pulmonary sepsis in 26 (29.9%), hemorrhagic shock in 12
(13.8%), aspiration in 8 (9.2%), resuscitation in 6 (6.9%),
multiple transfusion in 4 (4.6%). Causes of CPE included
congestive heart failure in 15 (44.1%), myocardial infarc-
tion/ischemia in 11 patients (32.4%), and acute volume
overload in 8 (23.5%).
Baseline Characteristics of the study population were
presented in Table 1 stratified according to the final expert
diagnosis. Echocardiographic data was obtained in 112
patients (92.6%) (81 patients of ARDS/ALI group, 31 patients
of CPE group), and hemodynamic data in 49 patients
(40.5%) (33 patients of ARDS/ALI group, 16 patients of CPE
group). Compared to patients with ARDS/ALI, patients with
CPE were significantly older and more likely to have
a history of heart failure or coronary artery disease, lower
LIS score and percentage of mechanical ventilation. Echo-
cardiographic data indicated patients with CPE had lower
left ventricular ejection fraction (LVEF) and higher
percentage of left ventricular dilatation. HemodynamicCharacteristics showed they had higher PAOP and mixed
venous oxygen saturation (SvO2) compared to subjects with
ARDS/ALI.Copeptin and NT-proBNP values
Patients with ARDS/ALI had significantly higher median
levels of copeptin compared to subjects with CPE
[52.53(29.81e91.43) pmol/L vs 25.14(21.04e34.26) pmol/
L, P < 0.001], and had significantly lower median levels of
NT-proBNP [1897(789.3e2890) pg/ml vs 5301(2842e7389)
pg/ml, P < 0.001] at enrollment (Table 1). The area under
ROC curve for copeptin in relation to the final diagnosis of
ARDS/ALI was 0.823  0.038 (Fig. 1A). At a cut point
>40.11 pmol/L, copeptin provided a specificity of 88.2%
and a sensitivity of 60.9% for the diagnosis of ARDS/ALI. At
a cut point <29.75 pmol/L, copeptin provided a specificity
of 75.9% and a sensitivity of 67.6% for the diagnosis of CPE.
The area under ROC curve for NT-proBNP to diagnose ARDS/
ALI was 0.875  0.037, the difference of AUC between
copeptin and NT-proBNP did not reach statistical signifi-
cance (p Z 0.369). The cut point of <2813 pg/ml had
a specificity of 79.4% and sensitivity of 65.5% for the diag-
nosis of ARDS/ALI, and the cut point of >4132 pg/ml had
a specificity of 88.9% and sensitivity of 70.6% for the diag-
nosis of CPE (Table 2). Combination of copeptin and pro-
BNP did not significantly increase AUC for the diagnose of
ARDS/ALI (AUC Z 0.818). When the analysis was restricted
to 82 patients (67.8%) without renal dysfunction (creatinine
clearance of >60 mL/min), the AUC for copeptin improved
to 0.857 and for NT-proBNP improved to 0.885.
Patients with ARDS/ALI were classified as septic group of
57 patients (65.5%) and non-septic group of 30 patients
(34.5%), the median copeptin levels at enrollment were
61.92(37.61e88.26) pmol/L and 29.42(22.91e62.73) pmol/
L respectively, the difference did not reach statistical
significance (P Z 0.125). The copeptin levels of septic
patients with ARDS/ALI were significantly higher than that
of patients with CPE [61.92(37.61e88.26) pmol/L vs
25.14(21.04e34.26) pmol/L, P < 0.001], while copeptin
levels of non-septic patients with ARDS/ALI were not
significantly higher than that of patients with CPE
[29.42(22.91e62.73) pmol/L vs. 25.14(21.04e34.26) pmol/
L, p Z 0.209]. The median NT-proBNP levels were 1776
(680.5e2755) pg/ml in septic group and 480.2(349.5e659.1)
pg/ml in non-septic group, the difference was significant
(P Z 0.047). Septic patents with ARDS/ALI had significant
lower NT-proBNP levels compared to patients with CPE
[1776(680.5e2755) pg/ml vs. 5301(2842e7389) pg/ml,
P < 0.001]. There were no significant differences between
pulmonary and non-pulmonary group in terms of copeptin
and NT-proBNP value.
In all patients, there is only a modest correlation
between concentration of copeptin and NT-proBNP
(r Z 0.52, P < 0.001). Copeptin levels at enrollment were
correlated with serum creatinine (r Z 0.64, P < 0.001),
osmolality (r Z 0.48, P Z 0.018), peripheral mean blood
pressure (r Z 0.32, P Z 0.021) and SvO2 (r Z 0.58,
P Z 0.024). NT-proBNP levels at enrollment were corre-
lated with age (r Z 0.62, P < 0.001), LVEF (r Z 0.64,
P Z 0.012) and creatinine (r Z 0.57, P < 0.001).
Table 1 Baseline characteristics of the study population.
Characteristics ARDS/ALI (n Z 87) CPE (n Z 34) p value
Demographics
Age, years 61(56e70) 70(66e75) 0.012*
Male, n (%) 42(48.3) 14(41.2) 0.481
BMI, kg/m2 22(19e24) 21(20e26) 0.798
Medical conditions, n (%)
Heart failure 6(6.9) 9(26.5) 0.003*
Atrial fibrillation 8(9.2) 7(20.6) 0.087
Coronary artery disease 6(6.9) 10(29.4) 0.001*
Chronic obstructive
pulmonary disease
11(12.6) 6(17.6) 0.477
Hypertension 21(24.1) 8(23.5) 0.944
Diabetes 15(17.2) 7(20.6) 0.668
Chronic kidney disease 8(9.2) 6(17.6) 0.191
Examination findings
APACHE-Ⅱscore 20(14e28) 16(12e25) 0.823
LIS score 3.1(2.3e3.6) 2.2(1.6e2.5) 0.024*
Heart rate, bpm 96(87e115) 92(78e112) 0.182
Systolic pressure, mmHg 116(91e132) 121(94e147) 0.412
Echocardiography
Patients examined, n (%) 81(93.1) 31(91.2)
LVEF, % 59(48e67) 51(34e55) 0.041*
Left ventricular dilatation, n(%) 8(9.8) 13(41.9) <0.001*
Right ventricular dilatation, n(%) 28(34.6) 9(29.0) 0.577
Ventilatory data
Mechanical ventilation, n(%) 48(55.2) 12(35.3) 0.049*
Arterial PH 7.43(7.35e7.47) 7.45(7.35e7.50) 0.506
Arterial lactate 1.2(0.9e1.7) 1.0(0.9e1.6) 0.731
PO2/FiO2 154(118e216) 199(110e248) 0.269
Hemodynamics
Patients examined, n (%) 33(37.9) 16(47.1)
PAOP, mmHg 13(9e15) 22(20e25) 0.012*
Cardiac index, L/min/m2 3.27(2.85e4.06) 3.11(2.24e3.96) 0.417
SvO2, % 61(52e68) 73(65e76) 0.046*
Laboratory findings
White blood cell, 109/L 11.9(8.7e17.7) 10.3(7.2e14.0) 0.330
Creatinine, mmol/L 76(50e107) 79(57e193) 0.342
Estimated creatinine
clearance, ml/min
71.2(40.2e120.6) 49.5(20.8e99.3) 0.314
Sodium, mmol/L 144(140e152) 143(139e146) 0.731
Albumin, g/L 30.1(28.2e33.1) 32.2(29.1e37.3) 0.081
Serum osmolality 310(305e328) 309(299e317) 0.309
Copeptin, pmol/L 52.53(29.81e91.43) 25.14(21.04e34.26) <0.001*
NT-proBNP, pg/ml 1897(789.3e2890) 5301(2842e7389) <0.001*
ARDS: acute respiratory distress syndrome; ALI: acute lung injury; CPE: cardiogenic pulmonary edema; BMI: body mass index; APACHE II:
acute physiology and chronic health evaluation II; LIS: lung injury score; NT-proBNP: N-terminal pro-B-type natriuretic peptide; LVEF:
left ventricular ejection fraction; PO2/FiO2: a ratio of arterial oxygen partial pressure and inspiratory oxygen fraction; PAOP: pulmonary
artery occlusion pressure.
Data were presented as median (interquartile range) for continuous variables and number (%) for categorical variables.
*P < 0.05.
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The mortality was 31.0% and 20.6% in patients with ARDS/
ALI and CPE respectively. The copeptin and NT-proBNP
levels at enrollment in surviving and non-surviving patients
were shown in Fig. 2. In patients with ARDS/ALI, the
copeptin value in non-survivors was significantly higherthan survivors [98.24(68.95e112.3) pmol/L vs
36.72(28.41e68.65) pmol/L, P < 0.001]. This difference
was also significant for NT-proBNP [2891(1689e3216) pg/ml
vs 1418 (619.8e2870) pg/ml, P Z 0.001]. In patients with
CPE, non-survivors had significant higher median levels of
copeptin compared to survivors [34.42(32.61e42.65) pmol/
L vs 23.52(19.81e28.94) pmol/L, P Z 0.002], and higher
Figure 1 ROC curves for copeptin and N-terminal pro-B-type
natriuretic peptide (NT-proBNP) in (A) diagnosing acute respi-
ratory distress syndrome (ARDS)/acute lung injury (ALI) and (B)
predicting 30-day mortality in patients with ARDS/ALI.
1272 Q. Lin et al.levels were also found for NT-proBNP [7653(6591e8901) pg/
ml vs 4690 (2679e6021) pg/ml, P Z 0.007].
In patients with ARDS/ALI, ROC curve were drawn to
evaluate the value of copeptin and NT-proBNP at enroll-
ment to predict 30-day mortality (Fig. 1B). The AUC was
calculated as 0.798  0.053 for copeptin and 0.722  0.056
for NT-proBNP, there was not a significant difference
between the AUC of copeptin and NT-proBNP (P Z 0.191).
Combination of copeptin and pro-BNP did not significantly
increase AUC for the prediction of mortality (AUCZ 0.734).Table 2 Diagnostic value of copeptin and NT-proBNP for ARDS/
Cut point Sensitivity Specificity
For ARDS/ALI
Copeptin > 40.11 0.609 0.882
NT-proBNP < 2813 0.655 0.794
For CPE
Copeptin < 29.75 0.676 0.759
NT-proBNP > 4132 0.706 0.889
ARDS: acute respiratory distress syndrome; ALI: acute lung injury; CP
type natriuretic peptide; PPV: positive predictive value; NPV: negat
tive likelihood ratios; AUC: area under the curve.The optimal cutoff value of copeptin for predicting death
was >68.35 pmol/L, which gave specificity of 73.8% and
sensitivity of 76.9%, and the cutoff value of NT-proBNP was
>2417 pg/ml, which provided specificity of 65.6% and
sensitivity of 61.5% .
KaplaneMeier curve were drawn according to the value
of 68.35 pmol/L for copeptin and 2417 pg/ml for NT-proBNP
as a cut-point to describe death over 30 days follow-up
(Fig. 3A, B). There was a significant difference in the
occurrence of death (P < 0.001 for copeptin, PZ 0.017 for
NT-proBNP). The KaplaneMeier analysis according to the
value of combining copeptin and NT-proBNP was shown in
Fig. 3C, patients with both higher copeptin and NT-proBNP
levels had significantly better survival time than patients
whose copeptin and NT-proBNP levels were both lower
(P < 0.001).
In patients with ARDS/ALI, linear regression models were
evaluated for the outcomes of VFD and non-pulmonary
OFD. Higher baseline plasma copeptin levels were strongly
associated with fewer VFD and non-pulmonary OFD
(P < 0.001) in analysis controlling for APACHEⅡ score, LIS
score, sepsis and creatinine value, while NT-proBNP levels
were not (P Z 0.075).
Univariate Cox regression analysis showed that APACHE
Ⅱscore, creatinine, plasma levels of copeptin, NT-proBNP at
enrollment were the common predictors of 30-day
mortality in patients with ARDS/ALI and patients with
CPE. In patients with ARDS/ALI, after adjustment for risk
factors (LIS, PO2/FiO2, sepsis, creatinine), multivariate Cox
regression analysis showed copeptin (HR Z 4.72,
P < 0.001), NT-proBNP (HRZ 2.18, PZ 0.026) and APACHE
Ⅱscore (HR Z 1.13, P Z 0.004) remained the independent
predictor for mortality (Table 3a). In patients with CPE,
after adjustment for covariates (APACHEⅡ, history of
coronary artery disease, LVEF), multivariate Cox regression
analysis showed predictor for mortality were copeptin
(HR Z 3.52, P Z 0.019), NT-proBNP (HR Z 2.61,
P Z 0.028), and creatinine (HR Z 1.26, P Z 0.032),
copeptin was also the strongest predictor (Table 3b).
In all patients, patients whose plasma copeptin and NT-
proBNP level increased over 4 days had a trend toward an
increased risk of death compared with those whose plasma
level decreased over time (mortality 42.9% vs. 22.1%,
P Z 0.021 for copeptin; mortality 40.5% vs. 21.5%,
P Z 0.027 for NT-proBNP). The association between
increasing copeptin and death was statistically significant
in patients with ARDS/ALI (HR Z 2.64, P Z 0.035) andALI and CPE.
PPV NPV LRþ LR- AUC
0.93 0.47 5.16 0.45 0.823
0.89 0.47 3.07 0.43 0.875
0.52 0.90 2.80 0.43 0.823
0.71 0.89 6.36 0.33 0.875
E: cardiogenic pulmonary edema; NT-proBNP: N-terminal pro-B-
ive predictive value; LRþ: positive likelihood ratios; LR: nega-
Figure 2 (A) Copeptin and (B) N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) levels in non-survivor (black) as
compared with survivor (gray) patients between acute respi-
ratory distress syndrome (ARDS)/acute lung injury (ALI) group
and cardiogenic pulmonary edema (CPE) group.
Copeptin assessment 1273patients with CPE (HR Z 1.62, P Z 0.029); the association
between increasing NT-proBNP and death was statistically
significant in patients with ARDS/ALI (HR Z 1.76,
P Z 0.042), while not in patients with CPE (Table 3).Discussion
In our study, we found that copeptin of >40.11 pmol/L had
a high specificity for the diagnosis of ARDS/ALI in patients
presenting with ARDS/ALI or CPE. Compared to NT-proBNP,
copeptin was a stronger prognostic marker for short-term
mortality.One of the practical property of copeptin is its stoi-
chiometric release together with AVP, the measurement of
AVP release through copeptin may be of relevance to
a variety of clinical situations. Our study showed copeptin
levels were 52.53(29.81e91.43) pmol/L in patients with
ARDS/ALI, the release of AVP in ARDS is most likely related
to these possible mechanisms. First, AVP has vasoconstric-
tive effect mediated via V1 receptor, which may correlate
to the hypoxia induced- vasoconstriction in hypoxemia.19
Increased concentrations of vasopressin may compensate
for V1 receptor down-regulation following exposure to
sustained hypoxemia.20 Our study did not find a direct
correlation of copeptin with PO2/FiO2, but showed a corre-
lation with SVO2 which could reflect the balance between
oxygen delivery and consumption. Second, the acute phase
of ARDS is characterized by widespread disruption of
alveolar-capillary barrier, leading to increased permeability
and thus the influx of protein-rich edema fluid into the
lung, and accompanying elevated extravasation and loss of
plasma volume. Consequently, the reduced effective
circulating volume, in turn, will stimulate the release of
AVP. Third, systemic response with recruitment of acti-
vated polymorpho-nuclear neutrophils releasing significant
components of lung inflammation and hyperpermeability.
The acute phase cytokines [interleukin (IL)-1b, IL-6, tumor
necrosis factor (TNF)-a] have been shown to enhance AVP
production.21 Endothelin-1 (ET-1) which is produced mainly
in the lung of patients with ARDS can potentiate AVP
secretion due to impaired pressor response and diminished
arterial baroreflex inhibition.22 Finally, in the course of
ARDS, pulmonary vasoconstriction induced by hypoxemia,
thromboembolism, interstitial edema and positive pressure
ventilation, all of which act together elevate pulmonary
artery pressure with subsequent right heart dysfunction.
The percentage of right ventricular dilatation in patients
with ARDS/ALI was 34.6% in our research. Pulmonary
hypertension patients display a noticeable activation of
AVP secondary to elevation of the pressure in the pulmo-
nary artery and aggravation of circulatory insufficiency.
Acute inflammation, endothelial cell activity, and
coagulation activation are suggested to be a higher degree
in sepsis-related ARDS than in non-sepsis-related ARDS.23
Moreover, studies suggested that 40%e50% of patients
with septic shock developed myocardial dysfunction,
characterized by depressed LVEF, reduced stroke volume
and low systemic vascular resistance.24 Adrenal insuffi-
ciency, which is common complication of sepsis, also
contributes to maintaining increased vasopressin levels.25
However, our findings did not support this conclusion.
Indeed, we found that there was no significant difference
between septic and non-septic group in terms of copeptin
levels, relative vasopressin deficiency might be an alter-
native explanation for this. In approximately one-third of
late septic shock patients, vasopressin levels are inappro-
priately low.26 The mechanisms propose for a possible
sepsis- associated dysfunction of the AVP system include
autonomic dysfunction of the afferent pathways and inad-
equate AVP production with consequent depletion of
neurohypophyseal stores. Sharshar et al26 observed a nega-
tive correlation between AVP plasma concentration and the
time after shock onset, this decline began as early as 6 h
after the diagnosis of septic shock. Because blood sampling
Figure 3 KaplaneMeier survival probability by (A) copeptin
value above or below the cut-point of 68.35 pmol/L, (B) N-
terminal pro-B-type natriuretic peptide (NT-proBNP) value
1274 Q. Lin et al.was performed in our study population within 12 h of ICU
admission, an initial AVP peak might have been missed. In
addition, hemorrhagic shock and resuscitation were the
main causes of ARDS/ALI in non-septic group, accompanied
with hypovolume and acidemia. AVP rises in response to
5%e10% decrease in blood volume by stimulating barore-
ceptor,27 meanwhile, arterial lactate levels are directly
associated with the AVP plasma levels. Thus, hemorrhagic
shock and successful cardiopulmonary resuscitation can
quickly lead to markedly increased copeptin and AVP
levels.28,29
AVP is an anti-diuretic and vasoconstricting hormone
activated in heart failure. Research has indicated copeptin
level elevates in acute decompensated heart failure and
acute myocardial infarction.11,12 Our study revealed that
the copeptin levels in patients with CPE were 25.14
(21.04e34.26) pmol/L. AVP is mainly stimulated in response
to a hyperosmolality and circulating volume depletion.30
Nevertheless, there is a deviation in the feedback mecha-
nism in patients with heart failure, and hypoosmolality is
consistently associated with high plasma AVP, resulting in
paradoxical water retention in already edematous states.31
On the other hand, nonosmotic AVP release occurs due to
activation of baroreceptor reflexes triggered by a reduction
in arterial pressure (secondary to reduced stroke volume or
arterial vasodilation).32 In the present study, the copeptin
levels of septic patients with ARDS/ALI were significantly
higher than that of patients with CPE, however, the
difference between non-septic patients with ARDS/ALI and
patients with CPE did not reach statistical significance.
Septic patients took a large proportion of our patients with
ARDS/ALI. These results indicated that sepsis might be one
important factor resulting in higher copeptin levels in
patients with ARDS/ALI. In addition, the characteristic
refractory hypoxemia of ARDS is primarily the result of
intrapulmonary shunting and increased ventilation/perfu-
sion mismatch. Based on our results, patients with ARDS/
ALI had lower SvO2 compared to subjects with CPE and
copeptin levels were correlated with SvO2, which might be
another possible interpretation of the greater copeptin
elevation in ARDS/ALI compared to CPE.
On the other hand, copeptin is a prognostic marker in
various of diseases. Similarly, our study showed that
copeptin value in non-survivors was significantly higher
than survivors and copeptin was the strongest determinant
of outcome in patients with ARDS/ALI and patients with
CPE. AVP is suggested to decrease cardiac index, compro-
mise oxygen delivery, and increase pulmonary vascular
resistance index in hypoxia19 and endotoxemia.33 Moreover,
AVP induces platelet aggregation and coagulation factor
release through stimulation of V1a receptor,
34 which can
aggravate the coagulation dysfunction in ARDS. In heart
failure, AVP leads to increased peripheral vasoconstriction,
increased renal water reabsorption and myocyte protein
synthesis.35 These alterations may in turn exacerbate the
cycle of AVP dysregulation and its detrimental effects.
Since then, clinical studies have demonstrated a potentialabove or below the cut-point of 2417 pg/ml, (C) combining
copeptin and NT-proBNP value above or below the cut-point.
Table 3 Cox proportional hazards models of patients with:
Variable Univariate Cox model Multivariate Cox model
HR (95% CI) p Value HR (95% CI) p Value
(a) ARDS/ALI for mortality prediction
APACHEⅡ (per point) 1.12 (1.06e1.19) 0.001 1.13 (1.05e1.21) 0.004
LIS (per point) 1.87 (1.23e3.26) 0.023
Creatininea (per unit) 1.37 (0.89e2.24) 0.019
Copeptina (per unit) 4.23 (2.16e8.13) <0.001 4.72 (2.48e7.16) <0.001
NT-ProBNPa (per unit) 2.52 (1.58e3.67) 0.021 2.18 (1.54e4.46) 0.026
Increase in copeptinb 2.98 (1.12e5.11) 0.019 2.64 (1.22e3.56) 0.035
Increase in NT-proBNPb 2.12 (1.25e4.23) 0.047 1.76 (1.14e3.01) 0.042
(b) CPE for mortality prediction
APACHEⅡ (per point) 1.08 (1.02e1.46) 0.026
Creatininea (per unit) 1.48 (0.78e2.76) 0.035 1.26 (0.73e4.28) 0.032
Copeptina (per unit) 3.72 (1.34e6.89) 0.014 3.52 (1.43e7.82) 0.019
NT-ProBNPa (per unit) 2.56 (1.54e5.26) 0.031 2.61 (1.14e5.67) 0.028
Increase in copeptinb 1.98 (1.35e3.26) 0.038 1.62 (1.21e3.12) 0.029
Increase in NT-proBNPb 1.39 (0.98e2.54) 0.047
ARDS: acute respiratory distress syndrome; ALI: acute lung injury; APACHE II: acute physiology and chronic health evaluation II; LIS: lung
injury score; NT-proBNP: N-terminal pro-B-type natriuretic peptide.
APACHE II: acute physiology and chronic health evaluation II; NT-proBNP: N-terminal pro-B-type natriuretic peptide.
a log-transformed to achieve normal distribution.
b Referent group: subjects whose copeptin/NT-proBNP decreased over 4 days.
Copeptin assessment 1275role of AVP receptor antagonist in the treatment of heart
failure, which can significantly reduce pulmonary capillary
wedge pressure and right atrial pressure leading to an
increase in free-water clearance.36 Furthermore, the
decrease in AVP and copeptin concentrations was accom-
panied by a clinically relevant improvement of cardiovas-
cular function in septic shock patients.37 In our study,
patients whose plasma copeptin level increased had an
increased risk of death compared with those whose plasma
level decreased over time.
Natriuretic peptide is a vasodilating and diuretic
hormone which greatly increase in diseases characterized
by an expanded fluid volume or increase of intraventricular
end-diastolic pressure. NT-proBNP measurement is a valu-
able assessment for the identification and exclusion of
acute congestive heart failure in patients with dyspnea.4
Based on our results, patients with CPE had significantly
higher median levels of NT-proBNP, lower LVEF and higher
percentage of left ventricular dilatation compared to
subjects with ARDS/ALI. The percentage of right and left
ventricular dilatation were 34.6% and 9.8% in patients with
ARDS/ALI respectively, right ventricular dysfunction may
play a more important role in ARDS. Left ventricular
dysfunction and wall tension are regarded as the primary
mechanism regulating NT-proBNP secretion.38 Although
increased stretching of the right ventricle and atrium may
cause BNP release, study has showed plasma BNP levels of
patients with impaired LVEF are remarkably higher than
that of patients with impaired right ventricular systolic
function.39 In addition, BNP level increases due to sepsis-
induced myocardial dysfunction or the direct effect of
inflammatory mediators in septic patients. BNP is positively
correlated with C-reactive protein (CRP) levels and
increases with sepsis severity.40,41 Our results wereconsistent with previous studies, the NT-proBNP levels of
septic group were significantly higher than that of non-
septic group in patients with ARDS/ALI.
Neuhold et al42 found that copeptin was superior to both
BNP and NT-proBNP in predicting mortality in heart failure
patients. The two hormones appear to reflect different
pathways leading to the deterioration of heart failure.
Although copeptin and BNP are independent predictors of
outcome in heart failure, favoring copeptin for the
prediction of death and combined end point, BNP for the
prediction of worsening chronic heart failure.43 We found
NT-proBNP was an independent predictor for mortality in
patients with ARDS/ALI and patients with CPE, whereas
copeptin was a superior prognostic marker.
There are several limitations to our study. First, the
number of patients with CPE was small and data derived
from a single-center study, prospective validation in larger
studies is needed to be replicated in multicenter. Second,
the absence of a single objective “gold standard” for
diagnosis of ARDS is a challenge inherent to all studies of
diagnostic testing for this syndrome. And finally, we did not
test the concentration of copeptin in alveolar fluid and
explore its diagnostic and prognostic value. Whether
copeptin levels can be used to guide clinical management
or shed further light on disease pathophysiology remains to
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